S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:REXN - Rexahn Pharmaceuticals Stock Price, Forecast & News

$2.84
-0.05 (-1.73 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$2.76
Now: $2.85
$2.94
50-Day Range
$1.96
MA: $2.33
$3.66
52-Week Range
$1.56
Now: $2.85
$9.18
Volume33,087 shs
Average Volume708,490 shs
Market Capitalization$11.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REXN
CUSIPN/A
Phone240-268-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.63 per share

Profitability

Net Income$-14,370,000.00

Miscellaneous

Employees10
Market Cap$11.43 million
Next Earnings Date3/13/2020 (Estimated)
OptionableOptionable

Receive REXN News and Ratings via Email

Sign-up to receive the latest news and ratings for REXN and its competitors with MarketBeat's FREE daily newsletter.


Rexahn Pharmaceuticals (NASDAQ:REXN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN."

When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work?

Shares of Rexahn Pharmaceuticals reverse split on the morning of Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) posted its earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.34. View Rexahn Pharmaceuticals' Earnings History.

When is Rexahn Pharmaceuticals' next earnings date?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Rexahn Pharmaceuticals.

What price target have analysts set for REXN?

2 brokers have issued 12-month target prices for Rexahn Pharmaceuticals' shares. Their forecasts range from $23.00 to $23.00. On average, they expect Rexahn Pharmaceuticals' share price to reach $23.00 in the next twelve months. This suggests a possible upside of 708.4% from the stock's current price. View Analyst Price Targets for Rexahn Pharmaceuticals.

What is the consensus analysts' recommendation for Rexahn Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rexahn Pharmaceuticals.

What are Wall Street analysts saying about Rexahn Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rexahn Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. " (10/29/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. The majority of contribution to our valuation comes from RX-3117, which represents over 65% of our price target. Remaining valuation comes from RX-5902 (Supinoxin) for triple negative breast cancer. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/8/2019)

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

Media stories about REXN stock have trended very negative on Monday, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rexahn Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Rexahn Pharmaceuticals.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 103,100 shares, a decline of 11.0% from the January 15th total of 115,800 shares. Based on an average trading volume of 59,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 2.6% of the company's shares are sold short. View Rexahn Pharmaceuticals' Current Options Chain.

Who are some of Rexahn Pharmaceuticals' key competitors?

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), SLS International (SLS), CorMedix (CRMD), Dynavax Technologies (DVAX), Novavax (NVAX), CytRx (CYTR), AcelRx Pharmaceuticals (ACRX), Madrigal Pharmaceuticals (MDGL) and Medallion Financial (MFIN).

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:
  • Douglas J. Swirsky, President, CEO, CFO, Secretary & Director
  • D J Kim, Vice President, Head-Research & Development
  • Lisa M. Nolan, Chief Business Officer

How do I buy shares of Rexahn Pharmaceuticals?

Shares of REXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of REXN stock can currently be purchased for approximately $2.85.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $11.43 million. The company earns $-14,370,000.00 in net income (profit) each year or ($5.28) on an earnings per share basis. Rexahn Pharmaceuticals employs 10 workers across the globe.View Additional Information About Rexahn Pharmaceuticals.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is http://www.rexahn.com/.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at 240-268-5300 or via email at [email protected]


MarketBeat Community Rating for Rexahn Pharmaceuticals (NASDAQ REXN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe REXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel